)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Alembic Pharmaceuticals
Alembic Pharmaceuticals (APLLTD) investor relations material
Alembic Pharmaceuticals Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary4 Nov, 2026
Executive summary
Q2 FY27 revenue was ₹2,603.48 crore, up 36% YoY; EBITDA margin expanded to 22.21% from 17.02%, and profit after non-controlling interests rose to ₹335.17 crore from ₹184.71 crore.
H1 FY27 revenue reached ₹4,753.25 crore, up 31% YoY; profit attributable to shareholders was ₹508 crore, up 50%.
All businesses recorded double-digit Q2 growth, led by U.S. and API, alongside India chronic momentum and growing U.S. Branded traction.
Financial highlights
Q2 gross margin was 73.7%, up 70 bps YoY; R&D was 8% of revenue.
Q2 PBT rose 95% YoY to ₹437.95 crore; EPS was ₹17.05 versus ₹9.40 a year earlier.
Q2 total income was ₹2,619 crore, up 37%; total expenses rose 29% to ₹2,179 crore.
H1 consolidated PBT was ₹659.81 crore versus ₹413.82 crore; EPS was ₹25.86 versus ₹17.25.
Outlook and guidance
FY27 consolidated revenue growth guidance increased to 20%-25%; U.S. business growth is expected up to 40%, API growth at least high teens, and ex-U.S. growth at mid-teens.
India and ex-U.S. outlooks were unchanged; India branded business targets market-level growth within 2-3 quarters, with acute portfolio recovery expected over coming quarters.
U.S. Branded is expected to break even by FY27 year-end or H1 FY28; FY28 is expected to have no branded margin drag.
FY28 U.S. growth of 10%-12% is conditional on launches progressing well; the margin aim is ~20% over FY28-29.
Continued investment targets product pipelines, complex platforms and specialty segments, including development of the U.S. Branded platform.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Alembic Pharmaceuticals
- FY24 profit rose, Sikkim operations resumed, and the audit qualification affects comparability only.APLLTD
Q4 23/24 - Demerger-year PAT reached Rs 85.39 crore as export formulations grew 70%.APLLTDQ4 10/11
- FY12 growth strengthened across formulations and exports, led by API exports up 55%.APLLTDQ4 11/12
- Profit grew faster than revenue as specialty products and global expansion advanced.APLLTDQ4 12/13
- FY14 profit rose 43% as regulated-market growth lifted returns and funded expansion.APLLTDQ4 13/14
- FY15 growth and wider margins backed a major investment-led push into new markets.APLLTDQ4 14/15
- US-led growth more than doubled profit as R&D and capacity investment accelerated.APLLTDQ4 15/16
- Earnings reset after a one-off US launch as investment accelerates toward complex generics and growth.APLLTDQ4 16/17
- Profit rose as investment built US reach, R&D depth and manufacturing capacity.APLLTDQ4 17/18
Next Alembic Pharmaceuticals earnings date
Q3 26/274 Feb, 2027
Alembic Pharmaceuticals
Next Alembic Pharmaceuticals earnings date
Q3 26/274 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Alembic Pharmaceuticals Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic and specialty medicines. The company produces active pharmaceutical ingredients (APIs) and formulations across various therapeutic areas, including cardiology, dermatology, neurology, and anti-infectives. The company is headquartered in Vadodara, India, and its shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).